Stock fact sheet · data as of

Canton Strategic Holdings Inc (CNTN): fair value, margin of safety and Wheel Score

Healthcare · Biotechnology · United States · Speculative / Distressed

Close1.87
GLS fair value0.50111 of 9 models
Margin of safety-273%price above fair value
Wheel Score22No optionscapped: no options
Health4/9Piotroski F-score
Moat1.4/10GLS 10-year score
Market cap$149M916k shares a day
Implied vol.-no listed options
P/E-EPS -0.45
Dividend yieldnone
Beta1.48moves more than the market
Next earnings16 Nov 2026in 31 days (before the open)

Is CNTN undervalued?

Canton Strategic Holdings Inc (CNTN) closed at 1.87 on 16 Oct 2026, 273% above the GLS average fair value of 0.5011. 1 of the 1 models that produced a number value the shares below the current price. A gap this wide usually means the market is paying for growth or a story the trailing numbers do not show yet; the models work from filed results, not forecasts, so they are conservative by design.

The average is built from just 1 models (DCF) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.

The nightly engine files CNTN under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for CNTN

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF0.5011-73%Present value of the projected free cash flows, discounted at the cost of capital
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)-1.30-170%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target0.0000-100%Analysts' average 12-month price target. Not in the average

Quality and financial health

Canton Strategic Holdings Inc scores only 4 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 1.4/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.

Returns on capital are thin or negative - ROIC -9.0%, ROE -9.0%, ROA -6.9% - with debt at 0.00 times equity and negative free cash flow.

Canton Strategic Holdings Inc pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Other Revenue 100% (quarter Q2 FY2026).

Institutional ownership scores 1/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score4 / 9ROIC-9.0%
GLS Moat1.4 / 10ROE-9.0%
Debt / equity0.00ROA-6.9%
Free-cash-flow yield-14.9%Payout ratio0%
Institutions1 / 10Insiders · Congress1 · 5 / 10

Wheel Score 22: No options

No options are listed on Canton Strategic Holdings Inc in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 22) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.

Volume runs at 916k shares a day on a market cap of $149M, with a beta of 1.48 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 11 of 20.

PartPointsFrom
Value0 / 25-273% margin of safety
Health9 / 20Piotroski 4/9
Moat2 / 15moat 1.4/10
Premium0 / 20no option data
Stability11 / 20916k shares/day, $149M cap, beta 1.48

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 16 Nov 2026 (before the open), 31 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Biotechnology

The 12 companies below are the closest to Canton Strategic Holdings Inc by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
CDXS
Codexis, Inc.
1.36--32Weak$149M
NBP
NovaBridge Biosciences
1.290.1073-1102%18Weak$149M
MENS
Jyong Biotech Ltd. Ordinary Shares
1.98--30Weak$151M
TARA
Protara Therapeutics, Inc.
2.481.03-140%20Weak$147M
MOLN
Molecular Partners AG
3.752.59-45%10No options$143M
KRSA
Korsana Biosciences, Inc.
33.656.74-399%13No options$158M
MDWD
MediWound Ltd.
12.21--43Weak$158M
IPHA
Innate Pharma S.A.
1.48--27No options$158M
PEPG
PepGen Inc.
2.321.01-129%19Weak$160M
ALXO
ALX Oncology Holdings Inc.
1.000.1291-674%25Weak$138M
NKTX
Nkarta, Inc.
1.93--34Weak$138M
CMPX
Compass Therapeutics, Inc.
0.89670.1228-630%26Weak$161M

⚖ Compare CNTN with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about CNTN

Is CNTN undervalued right now?

No: at 1.87 the stock trades 273% above the GLS average fair value of 0.5011 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.

What is the Wheel Score of CNTN and what does it mean?

CNTN has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".

What is the GLS fair value for CNTN?

0.5011 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does Canton Strategic Holdings Inc report earnings next?

The next earnings report is due on 16 Nov 2026 (before the open), 31 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does CNTN have listed options, and how liquid are they?

No. The nightly options snapshot found no listed contracts on CNTN, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.